An interventional study of Active tDCS and Sham tDCS in Tardive Dyskinesia, sponsored by Suzhou Psychiatric Hospital. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-24.
Sponsored by Suzhou Psychiatric Hospital · Not applicable, Interventional, and Treatment
Among 10 studies in Tardive Dyskinesia with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Tardive Dyskinesia · China.
Among the 10 studies in Tardive Dyskinesia with a site in China, this one is the only one that started in 2017, is one of 4 with no phase, and was the 4th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →3 of the 10 studies in Tardive Dyskinesia with a site in China are open now. Recruiting first, the newest first:
Peking University Sixth Hospital · Sites in China
Ages 18–65
Luye Pharma Group Ltd. · Sites in China
Ages 18–64
Shanghai Mental Health Center · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 64 across the 9 interventional studies, 180 across the 1 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 5 most frequent:
Suzhou Psychiatric Hospital is the lead sponsor of 2 studies on the registry; none are open to participants now.
Suzhou Psychiatric Hospital has 1 study filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
1 of the studies in Tardive Dyskinesia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07715994Shanghai Mental Health CenterA Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Tardive Dyskinesia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study was to evaluate the efficacy, safety, and cognitive function of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD).
This study is a randomized, double-blind, sham-controlled clinical trial. 60 patients with TD were randomly allocated to active (n=30) or sham tDCS groups (n=30). All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment). Abnormal Involuntary Movements Scale (AIMS), Tardive Dyskinesia Rating Scale (TDRS), Assessment of Negative Symptoms(SANS), the Positive and Negative symptom scale(PANSS), and the Cambridge Neuropsychological Test Automatic Battery (CANTAB) were assessed in patients. All evaluations were scored at baseline, the end of 3rd weeks, 5th weeks, and 7th weeks. Side effects of tDCS were assessed with an experimenter-administered open-ended questionnaire during the whole experiment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
Device: Active tDCS
For sham stimulation, the device was set to turn off after 30 seconds(study model).
Device: Sham tDCS
All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
For sham stimulation, the device was set to turn off after 30 seconds(study model).
Abnormal Involuntary Movements Scale
The primary outcome measure was the severity of TD symptoms, which was measured by the AIMS total score(the sum of items 1-7).The range for subscale scores(items1-7) is between 0-28 scores and the higher values represent a worse outcome.
Time frame: Change from baseline AIMS(items1-7) total scores at 3 weeks and 5 weeks and 7 weeks
Tardive Dyskinesia Rating Scale
The severity of TD symptoms were also measured by the total TDRS score and the orofacial dyskinesia subscale scores, trunk and limb dyskinesia subscale scores. The range for TDRS total score is between 44-264 scores and the orofacial dyskinesia subscale scores are between16-96 scores , the trunk and limb dyskinesia subscale scores are between 24-144 scores.The higher values represent a worse outcome.
Time frame: Change from baseline TDRS total scores at 3 weeks and 5 weeks and 7 weeks
Safety and Tolerabilit
Side effects of tDCS were assessed with an experimenter-administered open-ended questionnaire during the whole experiment. The questionnaire contained rating scales regarding the presence and severity of headache, difficulties in concentrating, acute mood changes, visual perceptual changes and any discomforting sensation like pain, tingling, itching or burning under the electrodes.
Time frame: We assessed the side affects during and after tDCS.
Scale for the Assessment of Negative Symptoms
Negative symptoms were assessed with SANS. The range for SANS total scores is between 0-120 scores and the higher values represent a worse outcome.
Time frame: Change from baseline SANS total scores at 5 weeks
Positive and Negative symptom scale
Psychopathology was measured by the total PANSS score and the positive, negative, and general psychopathology subscale scores. The range for PANSS total score is between 30-210 scores and the positive subscale scores are between 7-49 scores and the negative subscale scores are between 7-49 scores and the general psychopathology total scores are between 16-112 scores.
Time frame: Change from baseline PANSS total scores at 5 weeks
Cambridge Neuropsychological Test Automatic Battery
Each patient was given a series of computerized tests from the Cambridge Neuropsychological Test Automated Battery. The language-independent tests and touch screen technology deliver rapid and non-invasive cognitive assessment. Executive and memory function were assessed with the following three tasks:The Pattern Recognition Memory (PRM), Intra/Extradimensional Set Shift (IED), and Spatial Working Memory.
Time frame: Change from baseline cognitive function at 3 weeks and 5 weeks and 7 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Aug 2020, 36 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suzhou Psychiatric Hospital